Neurodegeneration startup launches with $50M, Amgen assets

Eight years after Atlas Venture began probing a group of nervous system cells and their effects in Alzheimer’s and other neurological disorders, the venture investor has launched a new startup with the help of an Amgen licensing deal.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.